AsedaSciences and EuroscreenFast Partner to add GPCR Screening of Chemicals into the 3RnD Toxicity Risk Ecosystem

Commercial sales and marketing agreement enhances 3RnD’s mechanistic toxicity screening panel, and expands the reach of ...

Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.
Business Wire

Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today ...
FierceBiotech

Verily links up with Sosei Heptares for GPCR drug discovery

G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers have discovered the vast potential for GPCR-targeting drugs in treating a range of health conditions, ...
Nasdaq

Interesting GPCR Put And Call Options For December 2026

Investors in Structure Therapeutics Inc (Symbol: GPCR) saw new options begin trading today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is ...